MERCAPTAMINE BITARTRATE
( DrugBank: Mercaptamine / KEGG DRUG: Cysteamine )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
19 | ライソゾーム病 | 10 |
19. ライソゾーム病
臨床試験数 : 899 / 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182
Showing 1 to 10 of 10 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2012-002773-64-IT (EUCTR) | 12/02/201420140212 | 21/11/201320131121 | A Long-Term Open-Label, Safety and Superior Effectiveness Study ofCysteamine Bitartrate Delayed-release Capsules (RP103) in Patients withCystinosis A Long-Term Open-Label, Safety and Superior Effectiveness Study ofCysteamine BitartrateDelayed-relea ... | A Long-Term Open-Label, Safety and Superior Effectiveness Study ofCysteamine Bitartrate Delayed-release Capsules (RP103) in Patients withCystinosis - RP103-07 A Long-Term Open-Label, Safety and Superior Effectiveness Study ofCysteamine BitartrateDelayed-relea ... | Cystinosis MedDRA version: 16.1;Level: PT;Classification code 10011777;Term: Cystinosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] Cystinosis MedDRA version: 16.1;Level: PT;Classification code 10011777;Term: Cystinosis;System Organ ... | Product Name: Cysteamine bitartrate (INN: mercaptamine bitartrate ) Product Code: RP103 INN or Proposed INN: mercaptamine bitartrate Product Name: Cysteamine bitartrate (INN: mercaptamine bitartrate ) Product Code: RP103 INN or Proposed INN: mercaptamine bitartrate Trade Name: CYSTAGON Product Name: Cystagon INN or Proposed INN: Cystagon Other descriptive name: Cysteamine bitartrate Trade Name: CYSTAGON Product Name: Cystagon INN or Proposed INN: Cystagon Other descriptive name: Cysteamine bitartrate Product Name: Cysteamine bitartrate(INN: mercaptamine bitartrate) Product Code: RP103 INN or Proposed ... | Raptor Therapeutics Inc. | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 3 | France;United States;Belgium;Netherlands;Germany;United Kingdom;Italy | ||
2 | EUCTR2012-002773-64-GB (EUCTR) | 22/01/201420140122 | 26/02/201320130226 | Study comparing the effectiveness of cysteamine bitartrate delayed release capsules (RP103) to Cystagon in Patients with Cystinosis(Adults and Children 12 years and older). Study comparing the effectiveness of cysteamine bitartratedelayed release capsules (RP103) to Cystag ... | A Long-Term Open-Label, Safety and Superior Effectiveness Study ofCysteamine Bitartrate Delayed-release Capsules (RP103) in Patients with Cystinosis - Superiority, Safety and Efficacy Study of RP103 in Cystinosis A Long-Term Open-Label, Safety and Superior Effectiveness Study ofCysteamine BitartrateDelayed-relea ... | Cystinosis MedDRA version: 20.0;Level: PT;Classification code 10011777;Term: Cystinosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] Cystinosis MedDRA version: 20.0;Level: PT;Classification code 10011777;Term: Cystinosis;System Organ ... | Trade Name: PROCYSBI Product Name: Cysteamine bitartrate (INN: mercaptamine bitartrate ) Product Code: RP103 INN or Proposed INN: mercaptamine bitartrate Trade Name: PROCYSBI Product Name: Cysteamine bitartrate (INN: mercaptamine bitartrate ) Product Code: RP103 INN or Proposed INN: mercaptamine bitartrate Trade Name: Cystagon 50mg Product Name: Cystagon INN or Proposed INN: mercaptamine bitartrate Trade Name: Cystagon 150mg Product Name: Cystagon INN or Proposed INN: mercaptamine bitartrate Trade Name: PROCYSBI Product Name: Cysteamine bitartrate(INN: mercaptamine bitartrate) Product Code: R ... | Horizon Pharma USA, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 3 | France;United States;Belgium;Netherlands;Germany;Italy;United Kingdom | ||
3 | EUCTR2012-002773-64-BE (EUCTR) | 21/01/201420140121 | 19/04/201320130419 | A Long-Term Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients with Cystinosis A Long-Term Open-Label, Safety and Superior Effectiveness Study of Cysteamine BitartrateDelayed-rele ... | A Long-Term Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients with Cystinosis - RP103-07 A Long-Term Open-Label, Safety and Superior Effectiveness Study of Cysteamine BitartrateDelayed-rele ... | Cystinosis MedDRA version: 14.1;Level: PT;Classification code 10011777;Term: Cystinosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] Cystinosis MedDRA version: 14.1;Level: PT;Classification code 10011777;Term: Cystinosis;System Organ ... | Product Name: Cysteamine bitartrate (INN: mercaptamine bitartrate ) Product Code: RP103 INN or Proposed INN: mercaptamine bitartrate Product Name: Cysteamine bitartrate (INN: mercaptamine bitartrate ) Product Code: RP103 INN or Proposed INN: mercaptamine bitartrate Trade Name: Cystagon 50mg Product Name: Cystagon INN or Proposed INN: MERCAPTAMINE BITARTRATE Trade Name: Cystagon 150mg Product Name: Cystagon INN or Proposed INN: MERCAPTAMINE BITARTRATE Product Name: Cysteamine bitartrate(INN: mercaptamine bitartrate) Product Code: RP103 INN or Proposed ... | Raptor Therapeutics Inc. | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 3 | United States;France;Belgium;Netherlands;Germany;United Kingdom;Italy | ||
4 | EUCTR2012-002773-64-NL (EUCTR) | 15/08/201320130815 | 01/11/201320131101 | Study comparing the effectiveness of cysteamine bitartrate delayed-release capsules (RP103) in Patients with Cystinosis (Adult and Children 12 years and older) Study comparing the effectiveness of cysteamine bitartratedelayed-release capsules (RP103) in Patien ... | A Long-Term Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients with Cystinosis - Superiority, Safety and Efficacy Study of RP103 in Cystinosis A Long-Term Open-Label, Safety and Superior Effectiveness Study of Cysteamine BitartrateDelayed-rele ... | Cystinosis MedDRA version: 20.0;Level: PT;Classification code 10011777;Term: Cystinosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] Cystinosis MedDRA version: 20.0;Level: PT;Classification code 10011777;Term: Cystinosis;System Organ ... | Trade Name: PROCYSBI Product Name: Cysteamine bitartrate (INN: mercaptamine bitartrate) Product Code: RP103 INN or Proposed INN: mercaptamine bitartrate Trade Name: PROCYSBI Product Name: Cysteamine bitartrate (INN: mercaptamine bitartrate) Product Code: RP103 INN or Proposed INN: mercaptamine bitartrate Trade Name: Cystagon 50mg Product Name: Cystagon INN or Proposed INN: mercaptamine bitartrate Trade Name: Cystagon 150mg Product Name: Cystagon INN or Proposed INN: mercaptamine bitartrate Trade Name: PROCYSBI Product Name: Cysteamine bitartrate(INN: mercaptamine bitartrate) Product Code: R ... | Horizon Pharma USA, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 3 | France;United States;Belgium;Germany;Netherlands;Italy;United Kingdom | ||
5 | EUCTR2012-002773-64-FR (EUCTR) | 03/06/201320130603 | 28/09/201520150928 | A Long-Term Open-Label, Safety and Superior Effectiveness Study ofCysteamine Bitartrate Delayed-release Capsules (RP103) in Patients withCystinosis A Long-Term Open-Label, Safety and Superior Effectiveness Study ofCysteamine BitartrateDelayed-relea ... | A Long-Term Open-Label, Safety and Superior Effectiveness Study ofCysteamine Bitartrate Delayed-release Capsules (RP103) in Patients withCystinosis - RP103-07 A Long-Term Open-Label, Safety and Superior Effectiveness Study ofCysteamine BitartrateDelayed-relea ... | Cystinosis MedDRA version: 18.0;Level: PT;Classification code 10011777;Term: Cystinosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] Cystinosis MedDRA version: 18.0;Level: PT;Classification code 10011777;Term: Cystinosis;System Organ ... | Product Name: Cysteamine bitartrate (INN: mercaptamine bitartrate ) Product Code: RP103 INN or Proposed INN: mercaptamine bitartrate Trade Name: Cystagon Product Name: Cystagon INN or Proposed INN: MERCAPTAMINE bitartrate Product Name: Cysteamine bitartrate(INN: mercaptamine bitartrate) Product Code: RP103 INN or Proposed ... | Raptor Therapeutics Inc. | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 3 | United States;France;Belgium;Netherlands;Italy;United Kingdom | ||
6 | EUCTR2010-018365-34-NL (EUCTR) | 14/12/201020101214 | 06/07/201020100706 | A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients with Nephropathic Cystinosis A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine BitartrateDelayed-release Capsules ... | A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients with Nephropathic Cystinosis - RP103-04 A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine BitartrateDelayed-release Capsules ... | Cystinosis MedDRA version: 20.0;Level: PT;Classification code 10011777;Term: Cystinosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] Cystinosis MedDRA version: 20.0;Level: PT;Classification code 10011777;Term: Cystinosis;System Organ ... | Trade Name: PROCYSBI Product Name: Cysteamine bitartrate (INN: mercaptamine bitartrate ) Product Code: RP103 INN or Proposed INN: mercaptamine bitartrate Trade Name: PROCYSBI Product Name: Cysteamine bitartrate (INN: mercaptamine bitartrate ) Product Code: RP103 INN or Proposed INN: mercaptamine bitartrate Trade Name: PROCYSBI Product Name: Cysteamine bitartrate(INN: mercaptamine bitartrate) Product Code: R ... | Horizon Pharma USA, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 3 | France;United States;Netherlands | ||
7 | EUCTR2009-017882-42-NL (EUCTR) | 19/10/201020101019 | 25/06/201020100625 | A Randomized, Crossover, Pharmacokinetic and PharmacodynamicStudy to Determine the Safety and Efficacy of Cysteamine BitartrateDelayed-release Capsules (RP103), Compared to Cystagon® in Patientswith Nephropathic Cystinosis A Randomized, Crossover, Pharmacokinetic and PharmacodynamicStudy to Determine the Safety and Effica ... | A Randomized, Crossover, Pharmacokinetic and PharmacodynamicStudy to Determine the Safety and Efficacy of Cysteamine BitartrateDelayed-release Capsules (RP103), Compared to Cystagon® in Patientswith Nephropathic Cystinosis A Randomized, Crossover, Pharmacokinetic and PharmacodynamicStudy to Determine the Safety and Effica ... | Cystinosis MedDRA version: 12.1;Level: LLT;Classification code 10011777;Term: Cystinosis | Product Name: Cysteamine bitartrate (INN: mercaptamine bitartrate Product Code: RP103 INN or Proposed INN: mercaptamine bitartrate Trade Name: Cystagon Product Name: Cysteamine bitartrate(INN: mercaptamine bitartrate Product Code: RP103 INN or Proposed I ... | Raptor Therapeutics Inc. | NULL | Not Recruiting | Female: yes Male: yes | 20 | Netherlands;France | |||
8 | EUCTR2010-020098-18-FR (EUCTR) | 09/09/201020100909 | 12/07/201020100712 | CrYSTobs A cohort of patients with cystinosis : compliance to cysteamine and neurological complicationsAn auxiliary study to Raptor RP103 03 and RP103 04 - CrYSTobs CrYSTobs A cohort of patients with cystinosis : compliance to cysteamine and neurological complicati ... | CrYSTobs A cohort of patients with cystinosis : compliance to cysteamine and neurological complicationsAn auxiliary study to Raptor RP103 03 and RP103 04 - CrYSTobs CrYSTobs A cohort of patients with cystinosis : compliance to cysteamine and neurological complicati ... | nephropatic cystinosis MedDRA version: 12.1;Level: LLT;Classification code 10011777;Term: Cystinosis nephropatic cystinosis MedDRA version: 12.1;Level: LLT;Classification code 10011777;Term: Cystinosis ... | Trade Name: CYSTAGON Product Name: CYSTAGON INN or Proposed INN: MERCAPTAMINE BITARTRATE Other descriptive name: CYSTEAMINE Product Name: RP 103 INN or Proposed INN: MERCAPTAMINE BITARTRATE Other descriptive name: CYSTEAMINE Product Name: RP 103 INN or Proposed INN: MERCAPTAMINE BITARTRATE Other descriptive name: CYSTEAMINE Trade Name: CYSTAGON Product Name: CYSTAGON INN or Proposed INN: MERCAPTAMINE BITARTRATE Other descript ... | HOSPICES CIVILS DE LYON | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | France | ||||
9 | EUCTR2009-017882-42-FR (EUCTR) | 12/08/201020100812 | 14/06/201020100614 | A Randomized, Crossover, Pharmacokinetic and PharmacodynamicStudy to Determine the Safety and Efficacy of Cysteamine BitartrateDelayed-release Capsules (RP103), Compared to Cystagon® in Patientswith Nephropathic Cystinosis A Randomized, Crossover, Pharmacokinetic and PharmacodynamicStudy to Determine the Safety and Effica ... | A Randomized, Crossover, Pharmacokinetic and PharmacodynamicStudy to Determine the Safety and Efficacy of Cysteamine BitartrateDelayed-release Capsules (RP103), Compared to Cystagon® in Patientswith Nephropathic Cystinosis A Randomized, Crossover, Pharmacokinetic and PharmacodynamicStudy to Determine the Safety and Effica ... | Cystinosis MedDRA version: 12.1;Level: LLT;Classification code 10011777;Term: Cystinosis | Product Name: Cysteamine bitartrate (INN: mercaptamine bitartrate ) Product Code: RP103 INN or Proposed INN: mercaptamine bitartrate INN or Proposed INN: mercaptamine bitartrate Trade Name: Cystagon Product Name: Cysteamine bitartrate(INN: mercaptamine bitartrate) Product Code: RP103 INN or Proposed ... | Raptor Therapeutics Inc. | NULL | Not Recruiting | Female: yes Male: yes | Phase 3 | France;Netherlands | |||
10 | EUCTR2010-018365-34-FR (EUCTR) | 00000000 | 18/06/201020100618 | A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients with Nephropathic Cystinosis - RP103-04 A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine BitartrateDelayed-release Capsules ... | A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients with Nephropathic Cystinosis - RP103-04 A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine BitartrateDelayed-release Capsules ... | Cystinosis MedDRA version: 12.1;Level: LLT;Classification code 10011777;Term: Cystinosis | Product Name: Cysteamine bitartrate (INN: mercaptamine bitartrate ) Product Code: RP103 INN or Proposed INN: mercaptamine bitartrate Product Name: Cysteamine bitartrate(INN: mercaptamine bitartrate) Product Code: RP103 INN or Proposed ... | Raptor Therapeutics Inc. | NULL | NA | Female: yes Male: yes | 20 | Phase 3 | France;Netherlands |